ClinicalTrials.gg
CompletedNCT02951819Updated Oct 8, 2021Results posted

A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma

A Phase 2 interventional study of Daratumumab and Cyclophosphamide in Multiple Myeloma, sponsored by Janssen Scientific Affairs, LLC. Completed at 26 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-08.

Sponsored by Janssen Scientific Affairs, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
101
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 132 studies testing daratumumab in Multiple Myeloma — 21 open to participants now, 63 under way, 10 of them phase 3. daratumumab · Multiple Myeloma.

Enrollment
40th of 132
101 · median 50
Started
2016
with 6 others
Phase 2
73 of 132
7 open now
Registered
20th of 132
by date

Among the 132 studies testing daratumumab in Multiple Myeloma, this one is the 40th largest by enrollment, is one of 7 that started in 2016, is one of 73 in phase 2, and was the 20th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

21 of the 132 studies testing daratumumab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About daratumumab

daratumumab: first FDA approval 2015 (DARZALEX), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies testing daratumumab in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate complete response plus (+) very good partial response (CR+VGPR) rate following 4 cycles of induction therapy of daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD), in previously untreated subjects, and in relapsed subjects with multiple myeloma, as defined by the International Myeloma Working Group (IMWG) criteria.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with documented multiple myeloma (MM) as defined by the International Myeloma Working Group (IMWG) 2015 criteria: Clonal bone marrow plasma cells greater than or equal to (>=) 10 percent (%) or -proven bony or extramedullary plasmacytoma and any one or more of the following CRAB (calcium level, renal dysfunction, anemia, and destructive bone lesions) features and myeloma defining events as in the protocol
  • Subjects with previously untreated myeloma or myeloma with one including an induction regimen which may be followed by stem cell transplantation and single agent maintenance therapy. For previously untreated subjects an emergency course of (defined as no greater than 40 milligram (mg) of dexamethasone, or equivalent per day for a maximum of 4 days) is permitted. In addition, radiation therapy is permitted prior to study entry, during screening, and during Cycles 1-2 of study treatment as needed for lytic bone disease
  • Have an (ECOG) performance status score of 0, 1, or 2
  • A woman of must have 2 negative serum (beta (β) human chorionic gonadotropin) or urine pregnancy tests during screening, the first one within 28 days prior to the first dose of study drug and the second within 24 hours prior to the first dose of study drug
  • A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of example, either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, and all men must also not donate sperm during the study and for 3 months after receiving the last dose of study drug

Exclusion criteria

Exclusion Criteria:

  • to any proteasome inhibitor (PI) or the combination of PI and immunomodulatory drug (IMiD) agents (such as lenalidomide), defined as failure to respond or progression within 60 days of the end of PI therapy
  • Exhibiting clinical signs of or has a known history of meningeal or central nervous system involvement by multiple myeloma
  • Has known with a (FEV1) less than (\<) 50 percent (%) of predicted normal
  • Has known moderate or severe persistent asthma within the past 2 years, or currently has uncontrolled asthma of any classification
  • Is known to be seropositive for , known to have surface antigen positivity, or known to have a history of
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    Dara-CyBorD

    Subjects will receive Daratumumab along with Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) as induction on a 28-day cycle length and Daratumab and Dexamethasone on Day 1 of each cycle for 12 cycles as maintenance therapy.

    Drug: Daratumumab · Drug: Cyclophosphamide · Drug: Bortezomib · Drug: Dexamethasone

Interventions

  • For induction therapy cycle 1 day 1 and day 2 doses of daratumumab will be 8 milligram/kilogram (mg/kg). Starting cycle 1 week 2 until the completion of week 8 of daratumumab patients will receive 16 mg/kg Intravenously (IV) weekly. Starting week 9 until the completion of week 24 therapy daratumumab will be administered every other week at 16 mg/kg IV. Starting week 25 and beyond for induction therapy daratumumab will be given once every 4 weeks.

  • Subjects will receive 4 to 8 cycles of oral cyclophosphamide 300 milligram per meter square (mg/m\^2 ) on Days 1, 8, 15, and 22 for every 28 days.

  • Subjects will receive 4 to 8 cycles of Bortezomib 1.5 mg/m2 subcutaneous (SC) on Days 1, 8, and 15 for every 28 days.

  • Subjects will be given corticosteroids (Dexamethasone) as pre-infusion therapy prior to daratumumab and for the first 8 cycles will also receive post-infusion corticosteroids (Dexamethasone).

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved Complete Response (CR) or Very Good Partial Response (VGPR)

    Percentage of participants who achieved CR or VGPR (as per International Myeloma Working Group \[IMWG\] criteria) was reported. CR: negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and less than (\<) 5 percent (%) plasma cells (PC) in bone marrow. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or greater than or equal to (\>=) 90% reduction in serum M-protein plus urine M-protein level \< 100 milligram per 24 hours (mg/24hours).

    Time frame: After 4 cycles of Induction (Approximately 4 months)

Secondary outcomes

  1. Overall Response Rate (ORR)

    ORR: percentage of participants achieved PR or better (PR,VGPR,CR,sCR) per IMWG. CR:negative immunofixation on serum, urine, disappearance of soft tissue plasmacytomas,\<5% PCs in bone marrow(BM). sCR:CR plus normal FLC ratio,absence of clonal cells in BM by immunohistochemistry, immunofluorescence. VGPR:Serum, urine M-protein detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum M-protein plus urine M-protein level \<100 mg/24hours. PR:\>=50% reduction of serum M-protein and reduction in 24hours urinary M-protein by \>=90% or to \<200mg/24hours. If serum, urine M-protein unmeasurable, a\>=50% decrease in difference involved and uninvolved FLC levels required in place of M-protein criteria. If serum, urine M-protein not measurable, serum free light assay is not measurable,\>=50% reduction in PCs required in place of M-protein,provided baseline bone marrow PCs% \>=30%, if present at baseline, a \>=50% reduction in size of soft tissue plasmacytomas is also required.

    Time frame: After 4 Cycles of Induction (4 months), at End of Induction (4 to 8 months) and at the End of Maintenance (12 months)

  2. Time to Very Good Partial Response (VGPR) or Better

    Time to VGPR or Better response was defined as duration from the date of first dose (start of induction) to the date of initial documentation of the response (VGPR or better) which was confirmed by a repeated measurement as required by the IMWG criteria. VGPR is defined by IMWG criteria as serum and urine M-protein detectable by immunofixation but not on electrophoresis or greater than or equal to (\>=) 90 % reduction in serum M-protein plus urine M-protein level \< 100 milligram/24 hours (mg/24 hours).

    Time frame: Up to 36 months

  3. Time to Partial Response (PR) or Better

    Time to PR or Better response was defined as duration from the date of first dose (start of induction) to the date of initial documentation of the response (PR or better) which was confirmed by a repeated measurement as required by the IMWG criteria. PR is defined as per IMWG criteria as \>= 50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by \>= 90% or to \< 200 mg/24hours. If the serum and urine M-protein are unmeasurable, a\>= 50% decrease in the difference between involved and uninvolved Free light chain (FLC) levels is required in the place of the M-protein criteria. If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, \>=50% reduction in plasma cells is required in place of M-protein, provided baseline bone marrow plasma cells percentage was \>=30%. In addition to the above listed criteria, if present at baseline, a \>= 50% reduction in the size of soft tissue plasmacytomas is also required.

    Time frame: Up to 12 months

  4. Duration of Response (DOR)

    DOR was defined for participants with a confirmed response (PR or better) as the duration from the date of initial documentation of a response (PR or better) according to the IMWG criteria to the date of first documented evidence of progressive disease according to the IMWG criteria or death due to progressive disease. PR:\>=50% reduction of serum M-protein and reduction in 24hours urinary M-protein by \>=90% or to \<200 mg/24hours. If serum and urine M-protein are unmeasurable, a \>=50% decrease in difference involved and uninvolved FLC levels required in place of M-protein criteria. If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, \>=50% reduction in PCs is required in place of M-protein, provided baseline bone marrow PCs % was \>=30%. In addition to the above criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas is also required.

    Time frame: Up to 36 months

  5. Progression Free Survival (PFS)

    PFS: duration from date of first dose (start of induction) to date of first documented evidence of progressive disease (PD) based on computerized algorithm per IMWG criteria or death due to any cause, whichever occurred first. PD: 25% increase from lowest response value in one of following: Serum and urine M-component (absolute increase \>=0.5 g/dL and \>=200 mg/24 hours respectively);Only participants without measurable serum and urine M-protein levels: difference between involved and uninvolved FLC levels (absolute increase\>10 mg/dL);Only participants without measurable serum and urine M-protein levels, without measurable disease by FLC levels, bone marrow PC% (absolute % \>=10%); Bone marrow PC%: absolute% \>10%; Definite development of new bone lesions/soft tissue plasmacytomas/definite increase in size of existing bone lesions/soft tissue plasmacytomas, Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder.

    Time frame: Up to 36 months

  6. Time to Disease Progression (TTP)

    TTP was defined as the time between the date of first dose (start of induction) and the date of first documented evidence of confirmed PD, as defined in the IMWG response criteria. PD per IMWG criteria: Increase of 25% from lowest response value in one of following: Serum and urine M-component (absolute increase \>=0.5 g/deciliter (dL) and \>=200 mg/24 hours respectively); Only participants without measurable serum and urine M-protein levels: difference between involved and uninvolved FLC levels (absolute increase\>10 mg/dL); Only participants without measurable serum and urine M-protein levels, without measurable disease by FLC levels, bone marrow PC% (absolute % \>=10%); Bone marrow PC%: absolute% \>10%; Definite development of new bone lesions/soft tissue plasmacytomas/definite increase in size of existing bone lesions/soft tissue plasmacytomas and Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to the PC proliferative disorder.

    Time frame: Approximately 15 months

  7. Overall Survival (OS)

    Overall survival (OS) was measured from the date of first dose (start of induction) to the date of death due to any cause.

    Time frame: Up to 36 months

  8. Percentage of Participants With Treatment Emergent-Adverse Event

    An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent were events between administration of study drug and approximately up to 36 months that were absent before treatment or that worsened relative to pre-treatment state.

    Time frame: Up to 36 months

07

Results

Posted Apr 3, 2019

Participant flow

Participant flow — Overall Study
MilestoneNewly Diagnosed Multiple Myeloma (NDMM)Relapsed Multiple Myeloma (RMM)
Started8714
Treated8614
Completed597
Not completed287
Withdrew: Death97
Withdrew: Withdrawal by subject30
Withdrew: Adverse event10
Withdrew: Lack of efficacy40
Withdrew: Lost to follow-up10
Withdrew: Progressive disease10
Withdrew: Other90

Outcome measures

PrimaryPercentage of Participants Who Achieved Complete Response (CR) or Very Good Partial Response (VGPR)

Percentage of participants who achieved CR or VGPR (as per International Myeloma Working Group \[IMWG\] criteria) was reported. CR: negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and less than (\<) 5 percent (%) plasma cells (PC) in bone marrow. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or greater than or equal to (\>=) 90% reduction in serum M-protein plus urine M-protein level \< 100 milligram per 24 hours (mg/24hours).

Time frame:
After 4 cycles of Induction (Approximately 4 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved Complete Response (CR) or Very Good Partial Response (VGPR)
Percentage of ParticipantsNewly Diagnosed Multiple Myeloma (NDMM)Relapsed Multiple Myeloma (RMM)
Percentage of Participants Who Achieved Complete Response (CR) or Very Good Partial Response (VGPR)44.2 (33.5 to 55.3)57.1 (28.9 to 82.3)
SecondaryOverall Response Rate (ORR)

ORR: percentage of participants achieved PR or better (PR,VGPR,CR,sCR) per IMWG. CR:negative immunofixation on serum, urine, disappearance of soft tissue plasmacytomas,\<5% PCs in bone marrow(BM). sCR:CR plus normal FLC ratio,absence of clonal cells in BM by immunohistochemistry, immunofluorescence. VGPR:Serum, urine M-protein detectable by immunofixation but not on electrophoresis or \>=90% reduction in serum M-protein plus urine M-protein level \<100 mg/24hours. PR:\>=50% reduction of serum M-protein and reduction in 24hours urinary M-protein by \>=90% or to \<200mg/24hours. If serum, urine M-protein unmeasurable, a\>=50% decrease in difference involved and uninvolved FLC levels required in place of M-protein criteria. If serum, urine M-protein not measurable, serum free light assay is not measurable,\>=50% reduction in PCs required in place of M-protein,provided baseline bone marrow PCs% \>=30%, if present at baseline, a \>=50% reduction in size of soft tissue plasmacytomas is also required.

Time frame:
After 4 Cycles of Induction (4 months), at End of Induction (4 to 8 months) and at the End of Maintenance (12 months)
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR)
Percentage of participantsNewly Diagnosed Multiple Myeloma (NDMM)Relapsed Multiple Myeloma (RMM)
After 4 Cycles of Induction79.1 (69.0 to 87.1)71.4 (41.9 to 91.6)
At the End of Induction87.2 (78.3 to 93.4)78.6 (49.2 to 95.3)
At the End of Maintenance89.5 (81.1 to 95.1)85.7 (57.2 to 98.2)
SecondaryTime to Very Good Partial Response (VGPR) or Better

Time to VGPR or Better response was defined as duration from the date of first dose (start of induction) to the date of initial documentation of the response (VGPR or better) which was confirmed by a repeated measurement as required by the IMWG criteria. VGPR is defined by IMWG criteria as serum and urine M-protein detectable by immunofixation but not on electrophoresis or greater than or equal to (\>=) 90 % reduction in serum M-protein plus urine M-protein level \< 100 milligram/24 hours (mg/24 hours).

Time frame:
Up to 36 months
Reported as:
Median · Months
Time to Very Good Partial Response (VGPR) or Better
MonthsNewly Diagnosed Multiple Myeloma (NDMM)Relapsed Multiple Myeloma (RMM)
Time to Very Good Partial Response (VGPR) or Better3.8 (2.8 to 4.9)1.8 (1.0 to 4.7)
SecondaryTime to Partial Response (PR) or Better

Time to PR or Better response was defined as duration from the date of first dose (start of induction) to the date of initial documentation of the response (PR or better) which was confirmed by a repeated measurement as required by the IMWG criteria. PR is defined as per IMWG criteria as \>= 50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by \>= 90% or to \< 200 mg/24hours. If the serum and urine M-protein are unmeasurable, a\>= 50% decrease in the difference between involved and uninvolved Free light chain (FLC) levels is required in the place of the M-protein criteria. If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, \>=50% reduction in plasma cells is required in place of M-protein, provided baseline bone marrow plasma cells percentage was \>=30%. In addition to the above listed criteria, if present at baseline, a \>= 50% reduction in the size of soft tissue plasmacytomas is also required.

Time frame:
Up to 12 months
Reported as:
Median · Months
Time to Partial Response (PR) or Better
MonthsNewly Diagnosed Multiple Myeloma (NDMM)Relapsed Multiple Myeloma (RMM)
Time to Partial Response (PR) or Better1.0 (1.0 to 1.0)1.0 (0.9 to 7.4)
SecondaryDuration of Response (DOR)

DOR was defined for participants with a confirmed response (PR or better) as the duration from the date of initial documentation of a response (PR or better) according to the IMWG criteria to the date of first documented evidence of progressive disease according to the IMWG criteria or death due to progressive disease. PR:\>=50% reduction of serum M-protein and reduction in 24hours urinary M-protein by \>=90% or to \<200 mg/24hours. If serum and urine M-protein are unmeasurable, a \>=50% decrease in difference involved and uninvolved FLC levels required in place of M-protein criteria. If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, \>=50% reduction in PCs is required in place of M-protein, provided baseline bone marrow PCs % was \>=30%. In addition to the above criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas is also required.

Time frame:
Up to 36 months
Reported as:
Median · Months
Duration of Response (DOR)
MonthsNewly Diagnosed Multiple Myeloma (NDMM)Relapsed Multiple Myeloma (RMM)
Duration of Response (DOR)NA (NA to NA)20.7 (5.9 to NA)
SecondaryProgression Free Survival (PFS)

PFS: duration from date of first dose (start of induction) to date of first documented evidence of progressive disease (PD) based on computerized algorithm per IMWG criteria or death due to any cause, whichever occurred first. PD: 25% increase from lowest response value in one of following: Serum and urine M-component (absolute increase \>=0.5 g/dL and \>=200 mg/24 hours respectively);Only participants without measurable serum and urine M-protein levels: difference between involved and uninvolved FLC levels (absolute increase\>10 mg/dL);Only participants without measurable serum and urine M-protein levels, without measurable disease by FLC levels, bone marrow PC% (absolute % \>=10%); Bone marrow PC%: absolute% \>10%; Definite development of new bone lesions/soft tissue plasmacytomas/definite increase in size of existing bone lesions/soft tissue plasmacytomas, Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder.

Time frame:
Up to 36 months
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsNewly Diagnosed Multiple Myeloma (NDMM)Relapsed Multiple Myeloma (RMM)
Progression Free Survival (PFS)NA (NA to NA)21.7 (6.8 to NA)
SecondaryTime to Disease Progression (TTP)

TTP was defined as the time between the date of first dose (start of induction) and the date of first documented evidence of confirmed PD, as defined in the IMWG response criteria. PD per IMWG criteria: Increase of 25% from lowest response value in one of following: Serum and urine M-component (absolute increase \>=0.5 g/deciliter (dL) and \>=200 mg/24 hours respectively); Only participants without measurable serum and urine M-protein levels: difference between involved and uninvolved FLC levels (absolute increase\>10 mg/dL); Only participants without measurable serum and urine M-protein levels, without measurable disease by FLC levels, bone marrow PC% (absolute % \>=10%); Bone marrow PC%: absolute% \>10%; Definite development of new bone lesions/soft tissue plasmacytomas/definite increase in size of existing bone lesions/soft tissue plasmacytomas and Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to the PC proliferative disorder.

Time frame:
Approximately 15 months
Reported as:
Median · Months
Time to Disease Progression (TTP)
MonthsNewly Diagnosed Multiple Myeloma (NDMM)Relapsed Multiple Myeloma (RMM)
Time to Disease Progression (TTP)NA (NA to NA)13.31 (6.80 to 13.31)
SecondaryOverall Survival (OS)

Overall survival (OS) was measured from the date of first dose (start of induction) to the date of death due to any cause.

Time frame:
Up to 36 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsNewly Diagnosed Multiple Myeloma (NDMM)Relapsed Multiple Myeloma (RMM)
Overall Survival (OS)NA (NA to NA)NA (11.30 to NA)
SecondaryPercentage of Participants With Treatment Emergent-Adverse Event

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent were events between administration of study drug and approximately up to 36 months that were absent before treatment or that worsened relative to pre-treatment state.

Time frame:
Up to 36 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment Emergent-Adverse Event
Percentage of participantsNewly Diagnosed Multiple Myeloma (NDMM)Relapsed Multiple Myeloma (RMM)
Percentage of Participants With Treatment Emergent-Adverse Event100.0100.0

Adverse events

Collected over Up to 36 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Newly Diagnosed Multiple Myeloma (NDMM)9/86 (10.5%)28/86 (32.6%)86/86 (100%)
Relapsed Multiple Myeloma (RMM)7/14 (50%)5/14 (35.7%)14/14 (100%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
EventNewly Diagnosed Multiple Myeloma (NDMM)Relapsed Multiple Myeloma (RMM)
PneumoniaInfections and infestations2/862/14
Haemorrhoidal HaemorrhageGastrointestinal disorders0/861/14
Toxicity to Various AgentsInjury, poisoning and procedural complications0/861/14
BronchiectasisRespiratory, thoracic and mediastinal disorders0/861/14
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders2/861/14
Atrial FibrillationCardiac disorders4/860/14
Non-Cardiac Chest PainGeneral disorders2/860/14
PyrexiaGeneral disorders2/860/14
Mental Status ChangesPsychiatric disorders2/860/14
Febrile NeutropeniaBlood and lymphatic system disorders1/860/14
Most frequent other events
Showing 10 of 405
Most frequent other events
EventNewly Diagnosed Multiple Myeloma (NDMM)Relapsed Multiple Myeloma (RMM)
FatigueGeneral disorders58/867/14
NauseaGastrointestinal disorders43/863/14
Upper Respiratory Tract InfectionInfections and infestations30/867/14
CoughRespiratory, thoracic and mediastinal disorders42/866/14
DiarrhoeaGastrointestinal disorders38/866/14
Back PainMusculoskeletal and connective tissue disorders27/866/14
VomitingGastrointestinal disorders25/865/14
NasopharyngitisInfections and infestations11/865/14
InsomniaPsychiatric disorders28/862/14
ConstipationGastrointestinal disorders27/860/14

Baseline characteristics

Baseline population included enrolled participants who received at least 1 dose (partial or complete) of study treatment (Dara-CyBorD).

Age, Continuous
Age, Continuous(years)Newly Diagnosed Multiple Myeloma (NDMM)Relapsed Multiple Myeloma (RMM)Total
Mean63.6 ± 966.4 ± 8.9764 ± 9
Sex: Female, Male
Sex: Female, Male(Participants)Newly Diagnosed Multiple Myeloma (NDMM)Relapsed Multiple Myeloma (RMM)Total
Female32436
Male541064
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Newly Diagnosed Multiple Myeloma (NDMM)Relapsed Multiple Myeloma (RMM)Total
Hispanic or Latino415
Not Hispanic or Latino791291
Unknown or Not Reported314
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Newly Diagnosed Multiple Myeloma (NDMM)Relapsed Multiple Myeloma (RMM)Total
American Indian or Alaska Native000
Asian202
Native Hawaiian or Other Pacific Islander000
Black or African American11011
White671481
More than one race000
Unknown or Not Reported606
Region of Enrollment
Region of Enrollment(Participants)Newly Diagnosed Multiple Myeloma (NDMM)Relapsed Multiple Myeloma (RMM)Total
UNITED STATES8614100
08

Study locations

26 sites
  • Mobile, Alabama, United States
  • Phoenix, Arizona, United States
  • Sedona, Arizona, United States
  • Tucson, Arizona, United States
  • Fayetteville, Arkansas, United States
  • Greenbrae, California, United States
  • Denver, Colorado, United States
  • Niles, Illinois, United States
  • Indianapolis, Indiana, United States
  • Louisville, Kentucky, United States
  • Bethesda, Maryland, United States
  • Columbia, Maryland, United States
  • Grand Rapids, Michigan, United States
  • Omaha, Nebraska, United States
  • Camden, New Jersey, United States
  • Albany, New York, United States
  • East Setauket, New York, United States
  • Fresh Meadows, New York, United States
  • Cincinnati, Ohio, United States
  • Eugene, Oregon, United States
  • Greenville, South Carolina, United States
  • Austin, Texas, United States
  • Dallas, Texas, United States
  • San Antonio, Texas, United States
  • Tyler, Texas, United States
  • Seattle, Washington, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Mar 2018, 15 months.

Results were first posted in Apr 2019, 1 year after primary completion.

Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's 15 months is below that.

Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2016
First posted
Nov 1, 2016
StartActual
Nov 9, 2016
Primary completionActual
Mar 8, 2018
CompletionActual
Aug 17, 2020
Results first posted
Apr 3, 2019
Last update
Oct 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02951819
Responsible party
Sponsor
First posted
Nov 1, 2016
Start date
Nov 9, 2016
Primary completion
Mar 8, 2018
Completion
Aug 17, 2020
Results posted
Apr 3, 2019
Last update
Oct 8, 2021

Study contacts

Janssen Scientific Affairs, LLC Clinical Trial
study director · Janssen Scientific Affairs, LLC

Oversight

Data monitoring committee
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Daratumumab · Cyclophosphamide · Bortezomib · Dexamethasone

Start the discussion